The Light Adjustable Lens has revolutionized cataract surgery moving the important decisions about final lens power to its ideal place: after surgery. This way, the process can be more precise than ever, accounting for lens shift and refractive changes during the healing process, to achieve the best possible outcome.
We know the Light Adjustable Lens is a switch from the usual method of choosing from pre-manufactured lens powers before surgery to hit your patients’ post-surgery targets. To support this switch, the accuracy of the Light Adjustable Lens has been documented in clinical studies.
The Light Adjustable Lens is a versatile premium lens that a growing number of surgeons are finding is customizable for many types of patients. Throughout the adjustment process, Light Adjustable Lens patients are engaged and participate in their care in a way other lenses can’t offer.
This truly customized approach has led to outcomes they and their doctors are excited about. Almost daily, we add to the list of clinics nationwide that are successfully integrating the Light Adjustable Lens into their workflow and finding that it is a worthwhile investment for their practices and their patients.
Macromers/polymers are not visible in the lens, and graphic is used only as an illustration.
ActivShield is a UV protection layer built into the Light Adjustable Lens. Along with UV glasses, ActivShield helps prevent accidental sunlight exposure from changing the lens prior to the final lock-in treatment.
Join us in changing the shape of cataract surgery; fill out the form below to receive our complete guide to the Light Adjustable Lens.
The LAL provides optimized vision for patient satisfaction.2
LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).
Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.
The LAL offers LASIK-like accuracy in cataract surgery.2,3
92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).
Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.
The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.
The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.